Similar results were seen in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, in which results for the participants with tight glycemic control demonstrated a significant decrease in CRP, which was more robust after adjusting for changes in BMI over the intervention period17. This evidence concerns the gene CRP and diabetes mellitus.